Henagliflozin Reducing Infarct Size After Priamry PCI in Patients With ST Segment Elevation Myocardial Infarction
Status:
Recruiting
Trial end date:
2024-10-01
Target enrollment:
Participant gender:
Summary
This Randomized controlled intervention study recruited patients diagnosed with ST-segment
elevation myocardial infarction (STEMI). A total of 240 patients were enrolled in either
Henagliflozin group or control group. Patients in Henggliflozin group will be given by oral
administration of Henggliflozin for 6 months post acute myocardial infarction. Prior to
procedure, dynamic changes in myocardial enzymes were monitored. Major cardiovascular events,
including non-fatal myocardial infarction, all-cause death, revascularization due to angina,
and hospitalization for acute heart failure. This study aims to assess the impact of
Henggelizin intervention on the reduction of myocardial infarction size (evaluated by cardiac
enzyme) and improvement of left ventricular remodeling in patients with ST-segment elevation
myocardial infarction.